NEJM:T细胞淋巴瘤

2015-06-22 MedSci MedSci原创

一名57的男子来院就诊,诉称其鼻子上出现结痂病变已有2个月余(如图A所示)。目前,鼻腔内偶尔会有血性的分泌物流出,但没有疼痛感及伴随其他的症状。计算机断层扫描检查未见有淋巴结肿大或转移的现象。无骨髓转移的迹象。经取多个部位组织活检,最终确诊该男子患有皮肤T细胞淋巴瘤。该男子经过一个疗程的放疗治疗后,症状明显消失(如图B所示)。三个月后,该男子出现了共济失调的症状。再次通过计算机断层扫描检查发现,其

一名57的男子来院就诊,诉称其鼻子上出现结痂病变已有2个月余(如图A所示)。
目前,鼻腔内偶尔会有血性的分泌物流出,但没有疼痛感及伴随其他的症状。计算机断层扫描检查未见有淋巴结肿大或转移的现象。无骨髓转移的迹象。经取多个部位组织活检,最终确诊该男子患有皮肤T细胞淋巴瘤。




该男子经过一个疗程的放疗治疗后,症状明显消失(如图B所示)。三个月后,该男子出现了共济失调的症状。再次通过计算机断层扫描检查发现,其小脑病变已累计脑桥及小脑,同时,肺部出现了新的结节现象。取肺部组织作活检,结果显示与复发性恶性T细胞淋巴瘤一致。

为了控制病情的发展,病人决定接受化疗并同意行自体干细胞移植手术。移植术后10个月,在最后一次随访中,发现该男子的症状有明显的好转。

关于T细胞淋巴瘤---

皮肤T细胞淋巴瘤(cutaneous T-cell lymphoma, CTCL)属于结外非何杰金淋巴瘤(Non-Hodgkin’s lymphoma, NHL)中的一种,是原发于皮肤的由T淋巴细胞克隆性增生造成的疾病,由一组临床表现、组织学特征、及病程预后各不相同的疾病组成。皮肤T细胞淋巴瘤占所有原发性皮肤淋巴瘤的75%-80%。近十年来,随着人们对淋巴瘤认识的深入,一些新的类型被发现,同时淋巴瘤的分型在不断的更新和进步。与其他部位的淋巴瘤相比,皮肤淋巴瘤的皮损易于发现并能及时进行活检,在疾病的诊断、分类及治疗方面发挥着重要作用。

原始出处:

Manaf Aljishi, M.B., Ch.B., and Catherine Barrow, M.B., Ch.B.Cutaneous T-Cell Lymphoma.N Engl J Med, June 18, 2015, 372:2437.DOI: 10.1056/NEJMicm1406401

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 stupidox

    图片真是醉人

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 nizongzan

    好恶心

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 nizongzan

    图片恶心呵呵

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 nizongzan

    知识很不错进步

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1702378, encodeId=220b1e0237835, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sun Mar 27 01:41:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29147, encodeId=e9492914e0a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:22:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29067, encodeId=652d2906e4d, content=图片真是醉人, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 21:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28971, encodeId=85d2289e188, content=好恶心, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28972, encodeId=6ed4289e250, content=图片恶心呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28973, encodeId=9293289e30d, content=知识很不错进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 16:13:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372609, encodeId=578813e2609f5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jun 24 14:41:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]

相关资讯

Oncotarget:抗β2微球蛋白单克隆抗体能改善硼替佐米的耐药性

硼替佐米(BTZ)是目前用于治疗多发性骨髓瘤和套细胞淋巴瘤的一种蛋白酶抑制剂,因其存在许多副作用及耐药性,硼替佐米在临床的广泛应用受到限制。研究认为,细胞存活和死亡受到细胞凋亡和自噬活动的交叉调节,而且,自噬可以通过抑制半胱天冬酶的清除抑制细胞凋亡。近来研究发现,自噬在调节化疗药物耐量性中起很重要的作用,BTZ可以激活肿瘤细胞的自噬。BTZ诱导的细胞自噬对于BTZ耐药的乳腺癌细胞非常重要,提示抑制

“淋巴瘤”为什么会产生放疗耐受性?

淋巴瘤,是T细胞或B细胞癌化后的一类血液癌症。我们都知道T细胞与B细胞是免疫系统的重要组成部分,然而一些未知的原因使得淋巴细胞脱离正常的生存周期,从而导致癌化的发生。至今淋巴瘤的发生机制仍不清楚。 目前针对淋巴瘤的治疗手段包括化学治疗,放射治疗以及骨髓移植。如果癌化细胞停留在淋巴结等部位,那么可以首先采用放射治疗的方法。然而,目前临床上放射治疗经常会遇到耐受的现象,而这其中的原因也不得而

JAMA:预防淋巴瘤化疗患者乙肝复发,恩替卡韦or拉米夫定?

尽管接受了拉米夫定预防性治疗,乙肝病毒复发仍然是淋巴瘤患者接受利妥昔单抗在内的化疗后出现的非常严重的并发症。在选择预防性抗病毒方案的选择上仍没有定论。 比较恩替卡韦和拉米夫定在预防乙肝表面抗原阳性患者接受R-CHOP化疗方案(包括利妥昔单抗、环磷酰胺、阿霉素、长春新碱、强的松)后乙肝病毒复发的疗效。 我们进行了一项随机、开放、3期试验,数据来自全国2008年2月至2012年12月共10家医疗中

2014 年血液系统恶性肿瘤研究进展大盘点

2014 年即将结束,在过去的一年血液系统恶性肿瘤有哪些研究进展呢?MEDSCAPE 邀请重量级专家对此进行了盘点,包括疾病诊疗及新药进展等方面。 多发性骨髓瘤(MM) 最近,国际多发性骨髓瘤工作组更新了 MM 的最新定义, 这将对临床产生重大影响。诊断 MM 除了必须要有 CRAB 症状(高钙血症、肾衰竭、贫血和骨质破坏),该定义还包括了可以预测早期 CRAB 症状的标记物。 过去我们

ASH 2014:PD-1在血液肿瘤领域展现巨大潜力

根据2014年第56届美国血液学会年会(ASH)上公布的数据,以默沙东Keytruda和百时美施贵宝Opdvio为代表的新一类抗癌免疫疗法PD-1/PD-L1抑制剂在缩小实体肿瘤方面已取得了巨大的成功。现在,这类药物在血液癌症领域也展现出了巨大潜力。 PD-1/PD-L1抑制剂展现血癌治疗潜力 根据会上公布的2项研究数据,对当前任何已获批药物均无治疗反应的晚期霍奇金淋巴瘤(HL)患者,接受Ke

Nature:T细胞疗法可延长白血病患者生存期?

当免疫学家Michel Sadelain在2007年时首次对一种经过基因工程改良的抗癌性T细胞进行试验时,他努力寻找着愿意参与该试验的患者。他所提出的治疗方案是:从肿瘤患者体内分离一些T细胞,利用基因工程技术对其进行改良,使其具有肿瘤识别能力,随后再将T细胞注射回患者体内;小鼠研究已经表明这种治疗方法具有可行性。但是Sadelain并没有因为同事拒绝提供患者而迁怒于他们。他说:“